Pacira Biosciences Inc (PCRX) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Pacira Biosciences inc   (NASDAQ: PCRX)
 

Pacira Biosciences Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Pacira Biosciences Inc inventory turnover ratio, the Pacira Biosciences Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 1.11 in the third quarter 2026, yet the ratio remained below the average, as PCRX's market remain challenging.Average inventory processing period, for the Pacira Biosciences Inc in Sep 30 2026 quarter, has decreased to 329 days, compare to 351 days, in the Jun 30 2026 quarter.

Within Healthcare sector 308 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 658 in the second quarter 2026, to 1797.

PCRX Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Pacira Biosciences Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PCRX Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth -17.88 % -9.17 % 12.42 % 22.02 % 40.96 %
Y / Y Cost of Sales Growth 8.62 % 8.07 % 6.14 % 1.04 % -11.8 %
Inventory Turnover Ratio (TTM) 1.11 1.04 1 1.01 1.06
PCRX's Total Ranking # 1797 # 658 # 1291 # 1139 #
Average inventory processing period 327 350 366 361 345
Seq. Inventory Growth -3.78 % -10.5 % -1.63 % -3.05 % 6.42 %
Seq. Cost of Sales Growth -15.69 % 21.29 % -9.64 % 17.57 % -16.12 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 309
Overall Market # 1797

Inventory Turnover Ratio Statistics
High Average Low
6.21 2.37 0.97
(Dec 31 2014)   (Dec 31 2025)



PCRX Company Profile >> Back to PCRX Efficiency Comparisons >> Compare PCRX Inventory Turnover Ratio to its Competitors

Financial Statements
Pacira Biosciences Inc 's Inventories $ 129 Millions Visit PCRX's Balance sheet
Pacira Biosciences Inc 's Cost of Revenues TTM $ 158 Millions Visit PCRX's Income Statement
What are PCRX's Sales? Visit PCRX's Sales by Segment

Other Inventory Turnover Ratios
Pacira Biosciences Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
PCRX's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for PCRX's Competitors
Inventory Turnover Ratio for PCRX's Suppliers
Inventory Turnover Ratio for PCRX's Customers

You may also want to know
PCRX's Sales Growth Rates PCRX's Pe Price to earnings ratio PCRX's Receivables Turnover Ratio PCRX's Stock Quote
PCRX's Net Income Growth Rates PCRX's Ps Price to Sales ratio PCRX's Sales per Employee PCRX's Asset Turnover Ratio
PCRX's Net Margin PCRX's Pb Price to Book ratio PCRX's Financial Strength Ratios PCRX's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Gilead Sciences Inc   3.30 $ 6,219.000  Millions$ 1,884  Millions
Iovance Biotherapeutics inc   3.21 $ 177.232  Millions$ 55  Millions
Teva Pharmaceutical Industries Limited  3.16 $ 8,011.000  Millions$ 2,537  Millions
Msa Safety Inc  3.00 $ 1,063.235  Millions$ 354  Millions
Mimedx Group Inc   2.98 $ 70.562  Millions$ 24  Millions
Abbott Laboratories  2.95 $ 20,765.000  Millions$ 7,032  Millions
Revvity Inc  2.93 $ 1,122.448  Millions$ 384  Millions
Ligand Pharmaceuticals Incorporated  2.93 $ 34.495  Millions$ 12  Millions
Zai Lab Limited  2.91 $ 200.083  Millions$ 69  Millions
Amneal Pharmaceuticals Inc   2.90 $ 1,910.255  Millions$ 658  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Ani Pharmaceuticals Inc  2.87 $ 405.540  Millions$ 142  Millions
Zevra Therapeutics Inc   2.82 $ 6.736  Millions$ 2  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Dentsply Sirona Inc   2.65 $ 1,769.000  Millions$ 668  Millions
Avita Medical Inc   2.58 $ 14.936  Millions$ 6  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Abeona Therapeutics Inc   2.46 $ 13.630  Millions$ 6  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Tela Bio Inc   2.35 $ 26.999  Millions$ 11  Millions
Mirum Pharmaceuticals Inc   2.35 $ 59.684  Millions$ 25  Millions
Aquestive Therapeutics Inc   2.34 $ 16.928  Millions$ 7  Millions
Lifevantage Corp  2.33 $ 39.482  Millions$ 17  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Rigel Pharmaceuticals Inc  2.24 $ 29.869  Millions$ 13  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions

Date modified: 2026-11-07T13:19:36+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.